{
  "study_id": "10.1200/JCO.2013.52.4694",
  "study_title": "Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)",
  "table_name": "Table 1",
  "table_title": "Patient Demographics and Clinical Characteristics for All Study Patients",
  "footnotes": [
    "Abbreviation: EGFR, epidermal growth factor receptor."
  ],
  "groups": [
    {
      "name": "Erlotinib",
      "n": 150,
      "type": "intervention"
    },
    {
      "name": "Docetaxel",
      "n": 151,
      "type": "intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Sex",
      "standardized_name": "Sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "Sex"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "Sex"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Female",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 42.0,
          "percentage": 28.0,
          "raw_string": "42 / 28.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 29.1,
          "raw_string": "44 / 29.1"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Male",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 108.0,
          "percentage": 72.0,
          "raw_string": "108 / 72.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 107.0,
          "percentage": 70.9,
          "raw_string": "107 / 70.9"
        }
      ]
    },
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "Age, years"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "Age, years"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "numeric_single",
          "value": 68.0,
          "raw_string": "68"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "numeric_single",
          "value": 67.0,
          "raw_string": "67"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age Range",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "numeric_mean_range",
          "range_min": 37.0,
          "range_max": 82.0,
          "raw_string": "37-82"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "numeric_mean_range",
          "range_min": 31.0,
          "range_max": 85.0,
          "raw_string": "31-85"
        }
      ]
    },
    {
      "original_label": "Stage",
      "standardized_name": "Cancer Stage",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "Stage"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "Stage"
        }
      ]
    },
    {
      "original_label": "IIIB",
      "standardized_name": "Cancer Stage IIIB",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Stage",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 20.0,
          "raw_string": "30 / 20.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 19.2,
          "raw_string": "29 / 19.2"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Cancer Stage IV",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Stage",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 120.0,
          "percentage": 80.0,
          "raw_string": "120 / 80.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 122.0,
          "percentage": 80.8,
          "raw_string": "122 / 80.8"
        }
      ]
    },
    {
      "original_label": "Performance status",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "Performance status"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "Performance status"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status 0",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Performance status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 77.0,
          "percentage": 51.3,
          "raw_string": "77 / 51.3"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 51.7,
          "raw_string": "78 / 51.7"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status 1",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Performance status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 67.0,
          "percentage": 44.7,
          "raw_string": "67 / 44.7"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 67.0,
          "percentage": 44.4,
          "raw_string": "67 / 44.4"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status 2",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Performance status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.0,
          "raw_string": "6 / 4.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.0,
          "raw_string": "6 / 4.0"
        }
      ]
    },
    {
      "original_label": "Smoking status",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "Smoking status"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "Smoking status"
        }
      ]
    },
    {
      "original_label": "Ever-smoker",
      "standardized_name": "Ever Smoker",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 74.0,
          "raw_string": "111 / 74.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 114.0,
          "percentage": 75.8,
          "raw_string": "114 / 75.8"
        }
      ]
    },
    {
      "original_label": "Never-smoker",
      "standardized_name": "Never Smoker",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 26.0,
          "raw_string": "39 / 26.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 24.5,
          "raw_string": "37 / 24.5"
        }
      ]
    },
    {
      "original_label": "Histology",
      "standardized_name": "Histology",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "Histology"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "Histology"
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma",
      "standardized_name": "Adenocarcinoma",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 69.3,
          "raw_string": "104 / 69.3"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 103.0,
          "percentage": 68.2,
          "raw_string": "103 / 68.2"
        }
      ]
    },
    {
      "original_label": "Squamous cell carcinoma",
      "standardized_name": "Squamous Cell Carcinoma",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 19.3,
          "raw_string": "29 / 19.3"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 32.0,
          "percentage": 21.2,
          "raw_string": "32 / 21.2"
        }
      ]
    },
    {
      "original_label": "Others",
      "standardized_name": "Other Histology",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 11.3,
          "raw_string": "17 / 11.3"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 10.6,
          "raw_string": "16 / 10.6"
        }
      ]
    },
    {
      "original_label": "First-line treatment",
      "standardized_name": "Prior First-Line Treatment",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 150.0,
          "percentage": 100.0,
          "raw_string": "150 / 100"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 151.0,
          "percentage": 100.0,
          "raw_string": "151 / 100"
        }
      ]
    },
    {
      "original_label": "Platinum doublet",
      "standardized_name": "Platinum Doublet",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line treatment",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 141.0,
          "percentage": 94.0,
          "raw_string": "141 / 94.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 140.0,
          "percentage": 92.7,
          "raw_string": "140 / 92.7"
        }
      ]
    },
    {
      "original_label": "Platinum doublet + bevacizumab",
      "standardized_name": "Platinum Doublet plus Bevacizumab",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line treatment",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.0,
          "raw_string": "6 / 4.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 6.6,
          "raw_string": "10 / 6.6"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other First-Line Treatment",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line treatment",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 / 2.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.7,
          "raw_string": "1 / 0.7"
        }
      ]
    },
    {
      "original_label": "Second-line treatment",
      "standardized_name": "Prior Second-Line Treatment",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 19.3,
          "raw_string": "29 / 19.3"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 13.9,
          "raw_string": "21 / 13.9"
        }
      ]
    },
    {
      "original_label": "Platinum doublet",
      "standardized_name": "Platinum Doublet",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Second-line treatment",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 12.7,
          "raw_string": "19 / 12.7"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 6.0,
          "raw_string": "9 / 6.0"
        }
      ]
    },
    {
      "original_label": "Platinum doublet + bevacizumab",
      "standardized_name": "Platinum Doublet plus Bevacizumab",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Second-line treatment",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 / 2.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 / 2.0"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other Second-Line Treatment",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Second-line treatment",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 4.7,
          "raw_string": "7 / 4.7"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 6.0,
          "raw_string": "9 / 6.0"
        }
      ]
    },
    {
      "original_label": "EGFR status",
      "standardized_name": "EGFR Mutation Status",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": "EGFR status"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": "EGFR status"
        }
      ]
    },
    {
      "original_label": "Wild-type",
      "standardized_name": "EGFR Wild-Type",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 109.0,
          "percentage": 72.7,
          "raw_string": "109 / 72.7"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 90.0,
          "percentage": 59.6,
          "raw_string": "90 / 59.6"
        }
      ]
    },
    {
      "original_label": "Exon 19 deletion or L858R",
      "standardized_name": "EGFR Exon 19 Deletion or L858R Mutation",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 14.0,
          "raw_string": "21 / 14.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 19.9,
          "raw_string": "30 / 19.9"
        }
      ]
    },
    {
      "original_label": "Other mutations",
      "standardized_name": "Other EGFR Mutations",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.3,
          "raw_string": "2 / 1.3"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 / 2.0"
        }
      ]
    },
    {
      "original_label": "Insufficient/not examined",
      "standardized_name": "EGFR Status Unknown",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 12.0,
          "raw_string": "18 / 12.0"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 18.6,
          "raw_string": "28 / 18.6"
        }
      ]
    }
  ]
}